TerminatedPhase 1

First in Human, Dose Escalation, Dose Expansion Study of AUR105

Stopped: Patient recruitment problems.

India17 participantsStarted 2022-11-30

Plain-language summary

This is a multi-center, open-label, First in Human, Phase 1 study of AUR 105 in adult patients with advanced malignancies. The study will have two parts: a Dose Escalation Part and Dose Expansion Part.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. At a minimum, solid tumor patients must have received at least two lines of systemic therapies in the metastatic incurable settings(these two lines must be in the metastatic setting and not in the earlier stage of cancer).
✓. At a minimum, lymphoma patients must have received at least 2 prior lines of systemic therapies. These systemic therapies could be either in the stage II, III or IV.

What they're measuring

Primary Endpoints

Timeframe: 28 Days

Primary Endpoints

Timeframe: Day 16

Primary Endpoints

Timeframe: Day 16

Primary Endpoints

Timeframe: Day 16

Primary Endpoints

Timeframe: Through study completion, an average of 1 year

Trial details

NCT IDNCT05605119

SponsorAurigene Discovery Technologies Limited

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-03-01

View on ClinicalTrials.gov More Solid Tumor, Adult trials